Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 5/20 | 1.00 |
| ▸ | MGAM | O43451 | 4/20 | 1.00 |
| ▸ | SI | P14410 | 4/20 | 1.00 |
| ▸ | MGAM2 | Q2M2H8 | 4/20 | 1.00 |
| ▸ | PKM | P14618 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | MAPT | P10636 | 5/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MYC | P01106 | 1/20 | 0.50 |
| ▸ | WDR5 | P61964 | 1/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27965552 | 0.84 | MGAM (0.72) | GAAMGAMSIMGAM2PKM | |
| SCHEMBL967793 | 0.82 | MGAM (0.69) | GAAMGAMSIMGAM2PKM | |
| SCHEMBL10749428 | 0.82 | MGAM (0.69) | GAAMGAMSIMGAM2PKM | |
| SCHEMBL368641 | 0.81 | MGAM (1.00) | GAAMGAMSIMGAM2PKM | |
| SCHEMBL7535965 | 0.79 | MGAM (0.66) | GAAMGAMSIMGAM2PKM | |
| SCHEMBL6153800 | 0.79 | GAA (0.64) | GAAMGAMSIMGAM2PKM | |
| SCHEMBL15130146 | 0.79 | MGAM (0.65) | GAAMGAMSIMGAM2PKM | |
| SCHEMBL16516070 | 0.78 | MGAM (0.64) | GAAMGAMSIMGAM2PKM | |
| SCHEMBL15130069 | 0.78 | MGAM (0.63) | GAAMGAMSIMGAM2PKM | |
| SCHEMBL6160095 | 0.77 | ROCK2 (0.69) | GAAMGAMSIMGAM2PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118221668-A | Indometacin derivative containing 2-amino-1, 3, 4-thiadiazole and preparation method and application thereof | 华南农业大学 | 2024-06-21 | — | — | CN | disclosed |
| CN-112920181-A | N- (5-phenyl-1, 3, 4-thiadiazole-2-yl) benzamide compound | 中国医科大学 | 2021-06-08 | — | — | CN | disclosed |
| US-9532989-B2 | Oxadiazolo[3,2-A]pyrimidines and thiadiazolo[3,2-A]pyrimidines | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-01-03 | — | — | US | disclosed |
| US-9532989-B2 | Oxadiazolo[3,2-A]pyrimidines and thiadiazolo[3,2-A]pyrimidines | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-01-03 | — | — | US | disclosed |
| US-20150374697-A1 | ORGANIC COMPOUNDS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2015-12-31 | — | — | US | disclosed |
| US-20150374697-A1 | ORGANIC COMPOUNDS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2015-12-31 | — | — | US | disclosed |
| US-20150374697-A1 | ORGANIC COMPOUNDS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2015-12-31 | — | — | US | disclosed |
| US-9066948-B2 | Oxadiazolo[3,2-a]pyrimidines and thiadiazolo[3,2-a]pyrimidines | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2015-06-30 | — | — | US | disclosed |
| US-9066948-B2 | Oxadiazolo[3,2-a]pyrimidines and thiadiazolo[3,2-a]pyrimidines | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2015-06-30 | — | — | US | disclosed |
| US-9066948-B2 | Oxadiazolo[3,2-a]pyrimidines and thiadiazolo[3,2-a]pyrimidines | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2015-06-30 | — | — | US | disclosed |
| US-20050065118-A1 | Organosulfur inhibitors of tyrosine phosphatases | METABASIS THERAPEUTICS, INC. | 2005-03-24 | — | — | US | disclosed |
| EP-1446110-A2 | ORGANOSULFUR INHIBITORS OF TYROSINE PHOSPHATASES | Structural Bioinformatics Inc. (US) | 2004-08-18 | — | — | EP | disclosed |
| WO-2003032916-A2 | ORGANOSULFUR INHIBITORS OF TYROSINE PHOSPHATASES | STRUCTURAL BIOINFORMATICS INC. (US) | 2003-04-24 | — | — | WO | disclosed |
| EP-0089730-B1 | GUANIDINO HETEROCYCLICPHENYLAMIDINES, PROCESSES FOR THEIR PREPARATION AND THEIR PHARMACEUTICAL USE | ISTITUTO DE ANGELI S.p.A. (IT) | 1987-05-27 | — | — | EP | disclosed |
| US-4645841-A | ANTIULCER AGENTS | ISTITUTO DE ANGELI, S.P.A. (IT) | 1987-02-24 | — | — | US | disclosed |
| US-4548944-A | ANTIULCER, ANTISECRETORY AGENTS | ISTITUTO DE ANGELI S.P.A. (IT) | 1985-10-22 | — | — | US | disclosed |
| EP-0089730-A2 | Guanidino heterocyclicphenylamidines, processes for their preparation and their pharmaceutical use | ISTITUTO DE ANGELI S.p.A. (IT) | 1983-09-28 | — | — | EP | disclosed |
| EP-0005783-B1 | IMIDAZO (2.1-B)-(1.3.4)-THIADIAZOLES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN MEDICAMENTS | BAYER AG (DE) | 1981-12-30 | — | — | EP | disclosed |
| US-4265898-A | ANTICOAGULANTS | BAYER AKTIENGESELLSCHAFT (DE) | 1981-05-05 | — | — | US | disclosed |
| EP-0005783-A1 | Imidazo (2.1-b)-(1.3.4)-thiadiazoles, process for their preparation and their use in medicaments | BAYER AG (DE) | 1979-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065118-A1 | Organosulfur inhibitors of tyrosine phosphatases | PTPRS, PTPRJ, PTPRCAP | GAA 2365/4885MGAM 3845/4885SI 4535/4885 |
| US-20150374697-A1 | ORGANIC COMPOUNDS | PLAT, ICAM1, VCAM1 | GAA 1692/4885MGAM 3501/4885SI 4217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.